Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

The rapid evolution of treatment strategies for hepatitis C.

Muir AJ.

Am J Gastroenterol. 2014 May;109(5):628-35; quiz 636. doi: 10.1038/ajg.2014.66. Epub 2014 Apr 15. Review.

PMID:
24732866
2.

The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.

Pearlman BL, Ehleben C, Perrys M.

Gastroenterology. 2015 Apr;148(4):762-70.e2; quiz e11-2. doi: 10.1053/j.gastro.2014.12.027. Epub 2014 Dec 31.

3.

Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.

Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK.

Ann Intern Med. 2015 Mar 17;162(6):407-19. doi: 10.7326/M14-1152.

PMID:
25775313
4.

My treatment approach to chronic hepatitis C virus.

Shiffman ML, Long AG, James A, Alexander P.

Mayo Clin Proc. 2014 Jul;89(7):934-42. doi: 10.1016/j.mayocp.2014.04.013. Epub 2014 May 24.

5.

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM.

Lancet. 2014 Nov 15;384(9956):1756-65. doi: 10.1016/S0140-6736(14)61036-9. Epub 2014 Jul 28. Erratum in: Lancet. 2014 Nov 15;384(9956):1748.

PMID:
25078309
6.

Sofosbuvir (Sovaldi┬░). Active against hepatitis C virus, but evaluation is incomplete .

[No authors listed]

Prescrire Int. 2015 Jan;24(156):5-10.

PMID:
25734194
7.

Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.

Saab S, Gordon SC, Park H, Sulkowski M, Ahmed A, Younossi Z.

Aliment Pharmacol Ther. 2014 Sep;40(6):657-75. doi: 10.1111/apt.12871. Epub 2014 Jul 28.

8.

Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.

Zhang S, Bastian ND, Griffin PM.

BMC Gastroenterol. 2015 Aug 5;15:98. doi: 10.1186/s12876-015-0320-4.

9.

Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.

Hagan LM, Sulkowski MS, Schinazi RF.

Hepatology. 2014 Jul;60(1):37-45. doi: 10.1002/hep.27151. Epub 2014 May 14.

10.

Hepatitis C virus therapy in the direct acting antiviral era.

Shiffman ML.

Curr Opin Gastroenterol. 2014 May;30(3):217-22. doi: 10.1097/MOG.0000000000000062. Review.

PMID:
24625897
11.

Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.

Welch NM, Jensen DM.

Liver Int. 2015 Jan;35 Suppl 1:11-7. doi: 10.1111/liv.12715. Review.

PMID:
25529082
12.

Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.

Shiffman ML, James AM, Long AG, Alexander PC.

Am J Gastroenterol. 2015 Aug;110(8):1179-85. doi: 10.1038/ajg.2015.218. Epub 2015 Jul 28.

PMID:
26215530
14.

HCV F1/F2 patients: treat now or continue to wait.

Shiffman ML, Benhamou Y.

Liver Int. 2014 Feb;34 Suppl 1:79-84. doi: 10.1111/liv.12408. Review.

PMID:
24373082
15.

Optimal therapy in genotype 4 chronic hepatitis C: finally cured?

Abdel-Razek W, Waked I.

Liver Int. 2015 Jan;35 Suppl 1:27-34. doi: 10.1111/liv.12724. Review.

PMID:
25529085
16.

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR; POSITRON Study; FUSION Study.

N Engl J Med. 2013 May 16;368(20):1867-77. doi: 10.1056/NEJMoa1214854. Epub 2013 Apr 23.

17.

Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.

Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, Ryland K, Chervenak AE, Watt KD, Vargas HE, Keaveny AP.

Hepatology. 2015 Jun;61(6):1880-6. doi: 10.1002/hep.27770. Epub 2015 Apr 27.

PMID:
25722203
18.

Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.

Rodriguez-Torres M, Gaggar A, Shen G, Kirby B, Svarovskaia E, Brainard D, Symonds WT, McHutchison JG, Gonzalez M, Rodriguez-Orengo J.

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):543-9. doi: 10.1097/QAI.0000000000000516.

PMID:
25622055
19.

Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.

Asselah T, Marcellin P.

Liver Int. 2014 Feb;34 Suppl 1:60-8. doi: 10.1111/liv.12424. Review.

PMID:
24373080
20.

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, H├ęzode C, Esteban R; VALENCE Investigators.

N Engl J Med. 2014 May 22;370(21):1993-2001. doi: 10.1056/NEJMoa1316145. Epub 2014 May 4.

Supplemental Content

Support Center